Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting-Reference-Cited by-同舟云学术

Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting

Published:2024-02-29 Issue:8 Volume:32 Page:895-902
ISSN:1018-4813
Container-title:European Journal of Human Genetics
language:en
Short-container-title:Eur J Hum Genet

Author:

Massmann Amanda^ORCID,Christensen Kurt D.^ORCID,Van Heukelom Joel,Schultz April^ORCID,Shaukat Muhammad Hamza Saad^ORCID,Hajek Catherine,Weaver Max,Green Robert C.^ORCID,Wu Ann Chen,Hickingbotham Madison R.^ORCID,Zoltick Emilie S.^ORCID,Stys Adam,Stys Tomasz P.

Funder

Foundation for the National Institutes of Health

Imagenetics Initiative and Sanford Chip Program from Sanford Health

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41431-024-01567-1.pdf

Reference40 articles.

1. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharm Ther. 2022;112:959–67.

2. McDermott JH, Leach M, Sen D, Smith CJ, Newman WG, Bath PM. The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack. Expert Rev Clin Pharm. 2022;15:811–25.

3. Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21:889–97.

4. Essa M, Ross JS, Dhruva SS, Desai NR, Yeh RW, Faridi KF. Trends in spending and claims for P2Y12 inhibitors by medicare and medicaid from 2015 to 2020. J Am Heart Assoc. 2023;12:e028869.

5. Danielak D, Pawlak K, Główka F, Karaźniewicz-Łada M. Influence of genetic and epigenetic factors of P2Y(12) receptor on the safety and efficacy of antiplatelet drugs. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07370-8.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of pharmacogenetic automated clinical decision support for clopidogrel;Pharmacogenomics;2024-09-11

2. Summer reading in EJHG;European Journal of Human Genetics;2024-07-31

3. Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?;Genes;2024-05-10

4. Early evaluation of a novel alert within cardiac procedural areas to facilitate genotype‐guided antiplatelet therapy;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-05-03